Related Experiment Video
Updated: Apr 30, 2026

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
Published on: October 6, 2023
Urologic manifestations of Erdheim-Chester disease
Daniel A Yelfimov1, Deborah J Lightner1, Matthew K Tollefson1
1Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN.
Insights
Erdheim-Chester disease (ECD) frequently affects the urinary system, causing issues like retroperitoneal infiltration and chronic kidney disease. Urologists must recognize ECD
Area of Science:
- Urology
- Histiocytosis
- Nephrology
Background:
- Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis.
- Retroperitoneal infiltration is a known manifestation of ECD.
- Urologic involvement in ECD is not well-characterized.
Purpose of the Study:
- To describe the spectrum of urologic manifestations in patients with Erdheim-Chester disease.
- To highlight the incidence and outcomes of urologic involvement in ECD.
- To raise awareness among urologists about potential urologic complications of ECD.
Main Methods:
- Retrospective review of 47 patients diagnosed with ECD between 1996 and 2012.
- Analysis of medical records and imaging for urologic involvement.
- Assessment of urologic manifestations including retroperitoneal infiltration, hydronephrosis, and chronic kidney disease.
Main Results:
- 79% of ECD patients exhibited urologic involvement.
- Common urologic manifestations included retroperitoneal infiltration (60%), diabetes insipidus (45%), chronic kidney disease (38%), and hydronephrosis (21%).
- 28% of patients required urologic surgery.
Conclusions:
- Urologic involvement in ECD is more common than previously reported.
- ECD can mimic other retroperitoneal diseases.
- Awareness of ECD is crucial for managing urologic symptoms such as lower urinary tract symptoms, hydronephrosis, and chronic kidney disease.
Objective:
To describe the urologic manifestations of Erdheim-Chester disease (ECD). ECD is a rare multisystem disorder of non-Langerhans cell histiocytosis. In addition to classic long bone involvement, the retroperitoneum is a well-established site of disease infiltration. Herein, we present the urologic manifestations and outcomes of ECD in a large series of patients.
Methods:
We identified 47 patients diagnosed with ECD between 1996 and 2012 at our institution. The medical records and imaging for these patients were reviewed for urologic involvement, including perirenal soft tissue encasement, renal atrophy, hydronephrosis, chronic renal insufficiency, diabetes insipidus, and lower urinary tract symptoms.
Results:
At diagnosis, the median patient age was 57 years (interquartile range 49, 68), and median follow-up after diagnosis was 3 years (interquartile range 1.8, 7.3). There were 31 male patients (66%) and 16 female patients (34%). The majority of these patients (37, 79%) demonstrated evidence of urologic involvement from ECD, requiring urologic surgery in 13 (28%). This urologic involvement included retroperitoneal infiltration (28, 60%), worsening lower tract urinary symptoms from diabetes insipidus (21, 45%), hydronephrosis (10, 21%), and chronic kidney disease (18, 38%).
Conclusion:
The incidence of urologic involvement with ECD is higher than previously reported in the published data. Urologists should be aware of this disorder, as it might mimic other retroperitoneal diseases and might contribute to lower urinary tract symptoms, hydronephrosis, renal atrophy, and chronic kidney disease.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Endocarditis II: Clinical Features of Infective Endocarditis
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome I : Introduction
Rheumatic Heart Disease I: Introduction
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...

